

# A new chronic ulcerative colitis model produced by combined methods in rats

Xue Liang Jiang<sup>1</sup> and Hui Fei Cui<sup>2</sup>

**Subject headings** colitis, ulcerative; animal model; 2, 4-dinitrochlorobenzene; acetic acids; apoptosis; flow cytometry; intestinal mucosa/pathology

Jiang XL, Cui HF. A new chronic ulcerative colitis model produced by combined methods in rats. *World J Gastroentero*, 2000;6(5):742-746

## INTRODUCTION

The etiopathogenesis of ulcerative colitis (UC) remains obscure, due to lack of an ideal animal model<sup>[1-8]</sup>. With the improvement of theory and methodology in the last 30 years, people used to adopt chemicals (acetic acid, ethanol, carrageen, etc.), immunotechniques (humoral or cellular immunity, immune complex) and substance derived from UC patients to set up various kinds of UC animal model, which mimic the pathologic changes of human UC, so far these remain far from reality<sup>[6-10]</sup>. A possible exception is the spontaneous colitis developed in the cotton-top tamarin when captured, but this animal is rarely available and expensive preventing its usage<sup>[11]</sup>. Therefore, establishing an ideal animal model becomes the focus and key of the research study of UC. Nowadays, the models produced by 2,4-dinitrochlorobenzene (DNCB) and acetic acid (AA) came into use because of their simplicity and pathologic changes simulating those of human UC<sup>[12-21]</sup>, however, the characteristics of short course of DNCB method and absence of immunoreactivity in AA method, these two models are not ideal either. In the present study, we established a new rat UC model produced by combination of DNCB and AA, and observed the changes of general condition, the disease course, the pathology, ultrastructure, apoptosis, immunoreaction and intracolonic pressure, in order to develop a more ideal UC animal model.

<sup>1</sup>Department of Gastroenterology, Chinese PLA General Hospital of Jinan Command, Jinan 250031, China

<sup>2</sup>Department of Biochemical Pharmaceutics, Shandong Medical University, Jinan 250012, Shandong Province, China

Dr. Xue Liang Jiang, graduated from Shandong Medical University as a postgraduate in 1993, associate professor of gastroenterology, major in immunology of digestive diseases, having 40 papers published.

**Supported by Key Research Fund of Jinan Command, No.9801**

**Correspondence to:** Dr. Xue Liang Jiang, Department of Gastroenterology, Chinese PLA General Hospital of Jinan Command, 25 Shifanlu, Jinan 250031, Shandong Province, China  
Tel. 0086-531-2600132, Fax. 0086-531-2029999 Ext.01166  
Email. chfjxl@jn-public.sd.cninfo.net

**Received** 2000-05-18 **Accepted** 2000-06-23

## MATERIALS AND METHODS

### Materials

Eighty healthy male and female adult Wistar rats weighing 250g - 350g were used in this study. They were provided by the Department of Experimental Animal of our hospital, and were raised in the SPF environment (constant temperature, humidity and sterilized water, food and padding) and acclimatized to the surrounding for 7 days prior to the experiments.

DNCB (First Reagent Factory of Shanghai), AA (Dongtai Reagent Factory), CD<sub>4</sub>, CD<sub>29</sub> and FITC or PE conjugated monoclonal antibodies (Immunotech, Marseilles, France), PC polygraf HR multichannel recording system (CTD-SYNECTICS Ltd), scanning electron microscope (EX1200, Japan), flow cytometry FACScan (Becton Dickinson Immunocytometry System).

### Methods

**Animal models** Eighty Wistar rats were divided randomly into 4 groups, 20 each. Group A (DNCB + AA): after the nape hair was depleted by 10% Na<sub>2</sub>S, DNCB acetone solution (20g/L) was dropped to the nape of the rats (0.3mL for each) once daily for 14 days, on the 15th day, nylon catheter (3mm in diameter) was inserted into the colon at the site of 8cm from the anus, and 0.25mL 0.1% DNCB, 50 mL/L 0.04 mol/L solution alcohol were infused, on the 16th day, 2mL AA solution (80mL/L) were infused into the same site for 15s, then 5mL normal saline (0.9%) was used to washout AA. Group B (DNCB only): from the 1st day to the 14th day, the method was similar to that for Group A, from the 15th day to the 18th day, 0.25 mL 0.1% DNCB (50 mL/L) alcohol solution (0.04mol/L) were infused into the colon at 8cm depth by the same nylon catheter once a day for each. Group C (AA only): 2mL AA (80mL/L) solution were infused into the colon at 8 cm depth by intracolonic administration with nylon catheter (3mm in diameter) for 15s, then 5mL saline for washing the AA. Group D (saline control): equivalent volume of normal saline was given in the method similar to that for Group A.

**Pathological observation** After the model had been established, the rats were killed at wk1, 2, 4, 8 and 16, and the distal colon (7cm-9cm) were removed longitudinally and washed to remove the luminal contents, tissues were fixed in 10% neutral-buffered formalin, dehydrated according to the routine, embedded in paraffin wax and sectioned.

Finally, the sections were stained with HE and observed microscopically. Apoptotic cells were identified morphologically<sup>[22]</sup>, for cell shrink age, chromatin condensation, formation of apoptotic bodies. Apoptosis was calculated randomly by counting the apoptotic bodies in the lamina propria for at least 200 cells<sup>[22]</sup>.

**Electron microscopy** The tissues were cut into small pieces (0.5mm in diameter) and fixed first in 2.5% glutaraldehyde buffered in 0.1M PBS (pH 7.2) at 4°C for at least 2h. The tissues were washed with the same buffer and then fixed in 1% osmium tetroxide in phosphate buffer at 4°C for 2h, dehydrated in graded series of acetone and embedded in epoxy resin 812. The ultra-thin sections were observed under EX1200 electron microscope.

**Measurement of CD<sub>4</sub><sup>+</sup>CD<sub>29</sub><sup>+</sup>** Blood CD<sub>4</sub><sup>+</sup>CD<sub>29</sub><sup>+</sup> were measured using flow cytometry according to our previous article<sup>[15,23]</sup>.

**Colonic pressure and motility** Intracolonic pressure and motility were measured according to our previous report through pressure transducer and recorded by PC Polygraf HR multichannel recording system<sup>[24]</sup> (Figure 1). During manometry, the catheter lumen was infused with 0.9% saline at 0.2mL/min using a miniature hydraulic infusion pump. The baseline resistance of intra colonic pressure was set at zero. The catheter (outer diameter 3mm with 4 side holes for 4 channels) was inserted into the colon at 9cm depth from the anus without laparotomy, and was withdrawn at 1mm-2mm increment, and measurement was not started until 5min after the tip of the catheter dropped out into the rectum.

**Statistical analysis** The data were expressed as  $\bar{x} \pm s$ , and analyzed, using the Student's *t* test  $P < 0.05$  was considered significant.

## RESULTS

**General condition and disease course** Anorexia, bloody diarrhea, mucus in stools were seen in all A, B and C groups after 1 to 2 weeks, which lasted for 16 weeks in group A with weight loss and 8 weeks in group C, while in group B, the bloody diarrhea and mucus in stools decreased gradually and recovered 2 weeks later. No symptoms were observed in group D.

**Pathological findings** Diffuse hemorrhage, edema, congestion, superficial ulceration in the mucosa with infiltration of lymphocytes, plasma cells and polymorphonuclear cells, cryptitis, crypt abscess could be observed in all A, B and C groups (Figure 2), and these characteristics lasted for 16 weeks in group A and 8 weeks in group C while only 2 weeks in group B. In group D, the bowel wall was normal by

gross and microscopic examinations.

**Ultrastructural changes** There were decreased number of cells, shortened microvilli, swollen mitochondria with depleted ridge, maldevelopment of goblet cell and increased number of lysosomes during the acute phase (Figure 3), which recovered to normal gradually (Figure 4).

**Apoptosis** The apoptosis indexes,  $9.9 \pm 3.8$  in group A,  $8.6 \pm 3.5$  in group B,  $8.1 \pm 2.9$  in group C, were significantly higher than those in group D ( $4.0 \pm 2.1$ ,  $P < 0.05$ ). Under scanning electronmicroscope, shrinkage of cells, condensation and margination of chromatin could be seen (Figure 5).

**Immunoreactivity** The changes of CD<sub>4</sub><sup>+</sup>CD<sub>29</sub><sup>+</sup> in ulcerative colitis models were shown in Table 1.

CD<sub>4</sub><sup>+</sup>CD<sub>29</sub><sup>+</sup> increased significantly ( $P < 0.01$ ) in group A and B but not in group C and D 1 week after set up of model ( $P > 0.05$ ).


**Table 1** Changes of CD<sub>4</sub><sup>+</sup>CD<sub>29</sub><sup>+</sup> in ulcerative colitis models (% ,  $\bar{x} \pm s$ )

Group	<i>n</i>	Prior to set up of model	1 week after set up of model
A	20	$5.01 \pm 2.01$	$11.17 \pm 2.18^b$
B	20	$4.95 \pm 1.87$	$10.98 \pm 2.87^b$
C	20	$4.93 \pm 1.96$	$5.06 \pm 2.03$
D	20	$4.76 \pm 1.56$	$4.91 \pm 1.93$

<sup>b</sup> $P < 0.01$  vs prior to set up of model.

**Colonic pressure and motility** One week after set up of the model in group A, the basal intracolonic pressure was apparently lower than that of the pre-model (proximal pressure:  $0.78 \text{ kPa} \pm 0.13 \text{ kPa}$  vs  $0.88 \text{ kPa} \pm 0.14 \text{ kPa}$ , distal pressure  $0.76 \text{ kPa} \pm 0.11 \text{ kPa}$  vs  $0.89 \text{ kPa} \pm 0.15 \text{ kPa}$ ,  $P < 0.05$ ). The frequency of migrating motor complex waves *in vivo* were significantly faster 1 week after set up of the model as compared with that prior to ( $1.59/\text{min} \pm 0.27/\text{min}$  vs  $0.60/\text{min} \pm 0.12/\text{min}$ ,  $P < 0.05$ ) in 7 rats of group A, this belonged to the pathologic colon of high dysrhythmia. The amplitude of migrating motor complex waves decreased markedly in 10 rats of group A after 1 week of post-model than that of pre-model (proximal pressure:  $0.64 \text{ kPa} \pm 0.24 \text{ kPa}$  vs  $1.98 \text{ kPa} \pm 0.38 \text{ kPa}$ , distal pressure:  $0.92 \text{ kPa} \pm 0.37 \text{ kPa}$  vs  $2.45 \text{ kPa} \pm 0.63 \text{ kPa}$ ,  $P < 0.01$ ), which belonged to asthenia colon. In the other 3 rats, while the proximal amplitude of migrating motor complex waves were lowered significantly ( $0.96 \text{ kPa} \pm 0.31 \text{ kPa}$ ), the distal amplitude of migrating motor complex waves remained still higher ( $2.35 \text{ kPa} \pm 0.50 \text{ kPa}$ ).

**Success rate** The ulceration pattern was present in all 20 rats of group A, the success rate therefore, could be considered 100%.



**Figure 1** Measurement of intracolonic pressure and motility in UC rats without laparotomy.

**Figure 2** Pathological features of ulcers and crypt abscess. HE×25

**Figure 3** Swelling of mitochondria with ridge depletion in goblet cell. ×4000

**Figure 4** In healing phase, the decreased number of the cell count and swelling of mitochondria recovered to normal gradually. ×10K

**Figure 5** Apoptosis of epithelia cell with condensation and margination of chromatin. ×12K

## DISCUSSION

So far, the precise etiopathogenesis of UC remained unelucidated<sup>[1,25-40]</sup>, though experimental colitis had been produced by various methods mimicking human UC somehow, up to the present there is not one ideal animal model which conforms with human UC in pathogenesis, pathology and biologic behavior<sup>[6-21,41,42]</sup>. An ideal animal model should fulfill the following requirements<sup>[15,24]</sup>: ① it should reflect the histological characteristics of the diseases; ② it should be autoimmune in nature; ③ it should have the similar clinical manifestations as in human UC; ④ it should be simple and reproducible. In this study, the UC model produced by AA method was related to its chemical stimulation to the colonic mucosa<sup>[12-14]</sup>, which led to increment of vascular permeability and activate inflammation mediators, resulting in bloody diarrhea, mucus in stools and histological features as diffuse edema, congestion and ulceration, crypt abscess and mucosal infiltration of inflammation cells. It can be used to study the inflammatory mechanism and anti-inflammatory drugs<sup>[43-45]</sup>, but it lacked the immune response which is a drawback.

DNCB is a hapten, when bound with tissue proteins will be able to elicit immunologic response and induce colitis<sup>[18-21]</sup>. The clinical symptoms and histological features, in particular  $CD_4^+CD_{29}^+$  cells are similar to those of human UC, but the self-limited course of 2 weeks, is too short to be utilized as an ideal model.

In order to overcome these shortcomings we establish a new chronic UC model by using DNCB and AA in combination which has the following advantages<sup>[15-17]</sup>. ① Clinically it manifests mucus in stools, bloody diarrhea and weight loss, just like those occur in human UC. ② It can reflect the pathologic characteristics of UC, such as continuous superficial colonic inflammation. Microscopically there exist mucosal edema and congestion, infiltration of lymphocytes, plasma cells and polymorphonuclear cells, crypt abscesses and ulceration. ③ It is an immune response model, immunology is well studied in UC<sup>[1,46-49]</sup>. One of the important immunoregulatory abnormality in UC is related to the T cell response<sup>[23,50]</sup>.  $CD_4$  interacts with HLA class II molecules,  $CD_4$  positive T cells can be divided into Th1 and Th2 cells whereas  $CD_{29}$  reacts with 130 KD integrin  $\beta_1$  subunit which is expressed as a heterodimeric complex with one of six  $\alpha$  subunits, forming the very late activation antigen (VLA) subfamily of adhesion receptors. The  $\beta_1$  subunit has a broad distribution, and is expressed on lymphocytes, monocytes but weakly on granulocytes. These receptors are involved in a variety of cell-cell and cell-matrix interactions. Co-expression of  $CD_4^+$  and  $CD_{29}^+$  can be used as a marker to identify the Th1 cells subgroup, whose main function is to help B lymphocyte to induce

antibody production and cell-mediated dissolution<sup>[15,23]</sup>. The increase of CD<sub>4</sub><sup>+</sup>CD<sub>29</sub><sup>+</sup> can lead to highly activated B lymphocyte and immunoregulatory abnormality. In this test, CD<sub>4</sub><sup>+</sup>CD<sub>29</sub><sup>+</sup> cells are significantly higher after the set up of models by combination of DNCB and AA, Which is in accord with the requirement of immune response similar to that in human UC. ④ It has a long disease course, if can last at least for 16 weeks with chronic damage of the bowel hence, eligible for the assessment of the drug effects. ⑤ The ultrastructural features are similar to those of human UC. The decreased number of epithelial cells and shortened microvilli, swelling of mitochondria with depletion of ridges can lead to impairment of water absorption of colon resulting in diarrhea. The maldevelopment of goblet cell, may lead to mucus in stools. ⑥ The above findings are not only consistent with the changes in human UC<sup>[51-59]</sup>, but also concordant with other reports<sup>[60,61]</sup>. The model produced by combination of DNCB and AA is a more ideal animal model of UC. Apoptosis was first described by Kerr<sup>[62]</sup> and is referred to as programmed cell death, which is genetically controlled. In active UC, injury is common. Did apoptotic cells increase in colonic epithelia which led to ulceration This hypothesis had been studied since 1996<sup>[63-67]</sup>. Apoptosis of the normal colon was localized in the superficial epithelium, far less than one apoptotic body per crypt. In active UC, the loss of epithelial cells occurred mainly by apoptosis in crypts of involved and uninvolved adjacent areas, resulting in impairment of protective mucosal barrier. The mediators of apoptosis are partly related to the Fas/Fas-L interaction and/or changes in Bcl-2 expression. Our previous study demonstrated the number of apoptotic cells of colonic mucosal epithelial cells in human UC increased as shown by flow cytometry<sup>[68]</sup>. This led to the damage of the barrier resulting in ulceration. Under scanning electron microscope, shrinkage of cells, condensation and margination of chromatin could all be seen.

The symptoms of diarrhea and abdominal pain are partly related with colonic motility disturbance<sup>[69-75]</sup>. In this study, we first used PC Polygraf HR multichannel recording system to measure the intracolonic pressure and motility in physiological and pathological conditions from multiple sites over prolonged periods. The resultant signals were digitized, analyzed and displayed in a readily interpretable manner, and could be easily subjected to a variety of statistical manipulations, as the colon was situated within the abdominal cavity, the temperature, humidity and pH were maintained by the rats themselves, and not interfered by operative maneuver. In this study, UC rats are characterized by decreased intracolonic basal pressure and disturbance of frequency and amplitude

of migrating motor complex which may lead to the symptoms of urgency, diarrhea and abdominal pain. In conclusion, the new chronic UC rat model produced by combination of DNCB and AA is similar to human UC in clinical manifestations, histology, ultrastructural changes, immune response, apoptosis and colonic motility, and it is simple, inexpensive and reproducible with high successful rate.

## REFERENCES

- Jiang XL, Quan QZ, Liu T, Dong XC. Recent advances in research of ulcerative colitis. *Shijie Huaren Xiaohua Zazhi*, 2000;8:216-218
- Jiang XL, Wang ZK, Qin CY. Current research and strategy on ulcerative colitis in China. *Shijie Huaren Xiaohua Zazhi*, 2000;8:610-613
- Yi JY, Xia B, Huang MF, Fu N, Deng CS. Observation of experimental model of ulcerative colitis in rats. *Xin Xiaohuabingxue Zazhi*, 1997;5:721-722
- He QX, Chen YB, Jia YL, Li XY, Jiang HY. The effects of immune complex on ulcerative colitis. *Huaren Xiaohua Zazhi*, 1998;6:87
- Zou YH, Zhang YB, Chen WQ, Zhong TJ, Liu XQ, Zhao H, Lian ZC, Su Q, Su XR, Huang HD. Effects of Chinese medicine compound Weichangkang on rat ulcerative colitis and its NO abnormality. *Huaren Xiaohua Zazhi*, 1998;6:288-290
- Gryglewski A, Szczepanik M, Szczepanik R. Colitis in laboratory experimentation. *Przegl Lek*, 1997;54:558-560
- Dieleman LA, Pena AS, Meuwissen SG, van Rees EP. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. *Scand J Gastroenterol*, 1997;223(Suppl):99-104
- Kim HS, Berstad A. Experimental colitis in animal models. *Scand J Gastroenterol*, 1992;27:529-537
- Strobe W. Animal models of inflammatory bowel disease-an overview. *Dig Dis Sci*, 1985;30:3s-10s
- Cominelli F, Dinarello CA. Interleukin 1 in the pathogenesis of and protection from inflammatory bowel disease. *Biotherapy*, 1989;1:369-375
- Warren BF. Cytokines in the cotton top tamarin model of human ulcerative colitis. *Aliment Pharmacol Ther*, 1996;10(Suppl):45-47
- Nosafova V, Bauer V. Protective effect of stobadine in experimental colitis. *Life Sci*, 1999;65:1919-1921
- Biondo Simoes M, De L, Sech M, Corbellini M, Schimarelli G, Veronese C, Ramos L, Collaco LM. Comparative study of the evolution of inflammatory colitis treated with an elemental diet, glutamine and 5 ASA. An experimental study in rats. *Arq Gastroenterol*, 1998;35:116-125
- Higa A, Eto T, Nawa Y. Evaluation of the role of neutrophils in the pathogenesis of acetic acid induced colitis in mice. *Scand J Gastroenterol*, 1997;32:564-568
- Jiang XL, Quan QZ, Wang D, Sun ZQ, Wang YJ. The changes of immunere sponse and ultrastructure in experimental colitis produced by combined methods in rats. *Shijie Huaren Xiaohua Zazhi*, 1999;7:381
- Jiang XL, Quan QZ, Wang D, Sun ZQ, Wang YJ, Qi F. Experimental study of ulcerative colitis treated with Herba Houttuyniae. *Shijie Huaren Xiaohua Zazhi*, 1999;7:786
- Jiang XL, Quan QZ, Wang D, Sun ZQ, Wang YJ, Qi F. Experimental ulcerative colitis produced by combined methods in rats. *Qinghai Yixueyuan Xuebao*, 1999;20:1-3
- Mack DR, Lau AS, Sherman PM. Systemic tumor necrosis factoralpha production in experimental colitis. *Dig Dis Sci*, 1992;37:1738-1745
- Rozga J. Ulcerative colitis in the experimental animal. *Acta Physiol Pol*, 1990;45:105-113
- Onderdonk AB. Experimental models for ulcerative colitis. *Dig Dis Sci*, 1985;30:40s-44s
- Meyers S, Sachar DB, Taub RN, Janowitz HD. Significance of anergy to dinitrochlorobenzene (DNCB) in inflammatory bowel disease: family and postoperative studies. *Gut*, 1978;19:249-252
- Chen XQ, Zhang WD, Song YG, Zhou DY. Induction of apoptosis of lymphocytes in rat mucosal immune system. *World J Gastroenterol*, 1998;4:19-23
- Jiang XL, Quan QZ, Wang D, Sun ZQ, Wang YJ, Qi F. Effect of glucocorticoid on lymphocyte adhesion molecule phenotype expression in patients with ulcerative colitis. *Zhongguo Weizhongbing Jijiu Yixue*, 1998;10:366-368
- Jiang XL, Quan QZ, Wang D, Sun ZQ, Wang YJ, Qi F. Effects of



- Herba Hou ttuyniae of colonic pressuer. *Shijie Huaren Xiaohua Zazhi*, 1999;7:639
- 25 Wu XN. Recent advances in mechanic study of ulcerative colitis. *Xin Xiaohuabingxue Zazhi*, 1995;3:129-131
- 26 Xia B, Crusius JBA, Meuwissen SGM, Pea AS. Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies. *World J Gastroentero*, 1998;4:446-458
- 27 Cui HF, Jiang XL. Treatment of corticosteroid resistant ulcerative colitis with oral low molecular weight heparin. *World J Gastroentero*, 1999;5:448-450
- 28 Xu CT, Wang RL, Ma LS. Alterations of serum motilin, peptide YY, IgG and ferritin in patients with ulcerative colitis. *Xin Xiaohuabingxue Zazhi*, 1997;5:247-248
- 29 Zhang L, Wang AM, Guo RF, Zhang WN. Serum soluble interleukin 2 receptor level in patients with ulcerative colitis. *Xin Xiaohuabingxue Zazhi*, 1997;5(4):251-252
- 30 Chen X, Zhang ZY, Xu ED, Na JH, Yang NH. Bone mineral density and serum Ca, P and Mg in ulcerative colitis patients. *Xin Xiaohuabingxue Zazhi*, 1997;5:385-386
- 31 Li HM. The mechanic study and characteristics of treatment in patients with ulcerative colitis. *Huaren Xiaohua Zazhi*, 1998;6:726-728
- 32 Jiang XL, Quan QZ, Sun ZQ, Wang YJ, Qi F, Wang D, Zhang XL. Expression of apoptosis on lymphocyte in patients with ulcerative colitis. *Shijie Huaren Xiaohua Zazhi*, 1999;7:903-904
- 33 Tai WP, Luo HS. Short chain fatty acids in pathogenesis and treatment of ulcerative colitis. *Shijie Huaren Xiaohua Zazhi*, 2000;8:96-97
- 34 Wen B, Ma GF. Determination of plasma nitric oxide, motilin and their significances in ulcerative colitis. *World J Gastroentero*, 1998;4(Suppl 2): 69
- 35 Wang JN, Li ZF, Fu Y, Ke Y, Xu YC, Lin GB. Changes of serum TNF $\alpha$  and IL-6 in patients with ulcerative colitis. *Shijie Huaren Xiaohua Zazhi*, 1999;7:727-728
- 36 Wu HG, Zhou LB, Pan YY, Huang C, Chen HP, Shi Z, Hua XG. Study of the mechanisms of acupuncture and moxibustion treatment for ulcerative colitis rats in view of the gene expression of cytokines. *World J Gastroentero*, 1999;5:515-517
- 37 Xia B, Shivananda S, Zhang GS, Yi JY, Crusius JBA, Pea AS. Inflammatory bowel disease in Hubei Province of China. *China Natl J New Gastroenterol*, 1997;3:119-120
- 38 Shivananda S. Epidemiology and disease outcome in inflammatory bowel disease: observations from the European Collaborative Study. *World J Gastroentero*, 1998;4(Suppl 2):25-26
- 39 Hu QY, Hu XY, Jiang Y. Clinical investigation of ulcerative colitis patients treated by integrated traditional Chinese and Western medicine. *World J Gastroentero*, 1998;4(Suppl 2):93-94
- 40 Wu HG, Zhou LB, Huang C, Pan YY, Chen HP, Shi Z, Hua XG. Gene expression of cytokines in acupuncture and moxibustion treatment for ulcerative colitis in rats. *Huaren Xiaohua Zazhi*, 1998;6:853-855
- 41 Zheng L, Gao ZQ, Wang SX. A chronic ulcerative colitis model in rats. *World J Gastroentero*, 2000;6:150-152
- 42 He QW, Chen YM, Jia YL, Li XY, Qian HY. Pathogenic effects of immune complexes. *Huaren Xiaohua Zazhi*, 1998;6:87
- 43 Cui SY, Zhang HB, Wu CZ, Sun GC, Zhao WP, Xu T, Li M. The clinical and experimental treatment of ulcerative colitis using Bupisan. *Xin Xiaohuabingxue Zazhi*, 1997;5:219-220
- 44 Zhu BX, Lu YM. Effect of sulfphasalazine on the colonic mucosal malondialdehyde in patients with ulcerative colitis. *Xin Xiaohuabingxue Zazhi*, 1997;5:619-620
- 45 Zhu BX, Lu YM, Ye SM. Effects of sulfphasalazine on oxygen free radicals in experimental colitis. *Xin Xiaohuabingxue Zazhi*, 1997;5:769-770
- 46 Jiang XL, Quan QZ, Liu TT, Wang YJ, Sun ZQ, Qi F, Ren HB, Zhang WL, Zhang L. Measurement of platelet activation in patients with ulcerative colitis. *Xin Xiaohuabingxue Zazhi*, 1997;5:736
- 47 Jiang XL, Quan QZ, Sun ZQ, Wang YJ, Qi F. Expression of adhesion molecules in tissues and peripheral lymphocyte of patients with ulcerative colitis. *Huaren Xiaohua Zazhi*, 1998;6:54-55
- 48 Jiang XL, Quan QZ, Sun ZQ, Wang YJ, Qi F, Wang D, Zhang XL. Detection of soluble CD44v6 in patients with inflammatory bowel disease. *Shijie Huaren Xiaohua Zazhi*, 1999;7:1028
- 49 Xia B, Guo HJ, Crusius JBA, Deng CS, Meuwissen SGM, Peña AS. *In vitro* production of TNF $\alpha$ , IL 6 and sIL 2R in Chinese patients with ulcerative colitis. *World J Gastroentero*, 1998;4:252-255
- 50 Jin W, Wu SH, Zhang ZJ, Lin PG, Ren ZQ, Sui WL. Effects of Changyanning on T lymphocyte subsets in patients with ulcerative colitis. *Shijie Huaren Xiaohua Zazhi*, 1999;7:616-617
- 51 Mughal S, Filipe MI. Ultrastructural study of inflammatory bowel disease. *Histol Histopathol*, 1992;7:599-605
- 52 Shields HM, Bates ML, Goldman H, Zuckerman GR, Mills BA, Best CJ, Bair FA, Goran DA, DeSchryver Kecskemeti K. Scanning electron microscopic appearance of chronic ulcerative colitis with and without dysplasia. *Gastroenterology*, 1985;89:62-72
- 53 Laschi R, Pasquinelli G, Versura P. Scanning electron microscopy application in clinical research. *Scanning Microsc*, 1987;1:1771-1795
- 54 Specian RD, Oliver MG. Functional biology of intestinal goblet cells. *Am J Physiol*, 1991;260:c183-193
- 55 O'Morain C, Smethurst P, Levi J, Peters TJ. Subcellular fractionation of rectal biopsy homogenates from patients with inflammatory bowel disease. *Scand J Gastroenterol*, 1985;20:209-214
- 56 Balazs M, Kovacs A. Ulcerative colitis: electron microscopic studies with special reference to development of crypt abscesses. *Dis Colon Rectum*, 1989;32:327-334
- 57 Mack DR, Lau AS, Sherman PM. Systemic tumor necrosis factor alpha production in experimental colitis. *Dig Dis Sic*, 1992;37:1738-1745
- 58 Kao HW, Zipser RD. Exaggerated prostaglandin production by colonic smooth muscle in rabbit colitis. *Dig Dis Sci*, 1988;33:697-704
- 59 Delpre G, Avidor I, Steinherz R, Kadish U, Ben Bassat M. Ultrastructural abnormalities in endoscopically and histologically normal and involved colon in ulcerative colitis. *Am J Gastroenterol*, 1989;84:1038-1046
- 60 Rumessen JJ. Ultrastructure of interstitial cells of Cajal at the colonic submucularis border in patients with ulcerative colitis. *Gastroenterology*, 1996;111:1447-1455
- 61 Kaftan SM, Wright NA. Studies on the mechanisms of mucous cell depletion in experimental colitis. *J Pathol*, 1989;159:75-85
- 62 Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon on with wild ranging implications in tissue kinetics. *Br J Cancer*, 1972;26:239-245
- 63 Ueyama H, Kiyohara T, Sawada N, Isozaki K, Kitamura S, Kondo S, Miyagawa J, Kanayama S, Shicnomura Y, Ishikawa H, Ohtani T, Nezu R, Nagata S, Matsuzawa Y. High fas ligand expression on lymphocytes in lesions of ulcerative colitis. *Gut*, 1998;43:48-55
- 64 Strater J, Wellisch I, Riedl S, Walczak H, Koretz K, Tandara A, Krammer PH, Moller P. CD95(APO 1/Fas) mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. *Gastroenterology*, 1997;113:160-167
- 65 Iwamoto M, Koji T, Makiyama K, Kobayashi N, Nakane PK. Apoptosis of crypt epithelial cells in ulcerative colitis. *J Pathol*, 1996;180:152-159
- 66 Kraus MD, Shahsafaei A, Antin J, Odze RD. Relationship of Bcl-2 expression with apoptosis and proliferation in colonic graft versus host disease. *Hum Pathol*, 1998;29:869-875
- 67 Sakai T, Kimura Y, Ohara KI, Kusugami K, Lynch DH, Yoshikai Y. Fas mediated cytotoxicity by intestinal intraepithelial lymphocyte during acute-graft versus host disease in mice. *Gastroenterology*, 1997;113:167-174
- 68 Jiang XL, Quan QZ, Chen GR, Sun ZQ, Wang YJ, Wang YP. Expression of apoptosis in tissues of ulcerative colitis. *Shijie Huaren Xiaohua Zazhi*, 2000;8:107-10
- 69 Reddy SN, Bazzocchi G, Chan S, Akashi K, Villanueva Meyer J, Yanni G, Mena I, Snape WJ. Colonic motility and transit in health and ulcerative colitis. *Gastroenterology*, 1991;101:1289-1297
- 70 Muraoka M, Kimura G, Zhaopeng H, Takada K. Ulcerative colitis: colon delivery of 5 aminosilyclic acid. *Nippon Rinsho*, 1998;56:789-794
- 71 Rao SS, Read NW. Gastrointestinal motility in patients with ulcerative colitis. *Scand J Gastroenterol*, 1990;172(Suppl):22-28
- 72 Snape WJ, Kao HW. Role of inflammatory mediators in colonic smooth muscle in ulcerative colitis. *Dig Dis Sci*, 1988;33:65s-70s
- 73 Sethi AK, Sarna SK. Colonic motor response to a meal in acute colitis. *Gastroenterology*, 1991;101:1537-1546
- 74 Aube AC, Cherbut C, Barbier M, Xing JH, Roze C, Galmiche JP. Altered myoelectrical activity in noninflamed ileum of rat colitis induced by trinitrobenzene sulphonic acid. *Neuogastroentero Motil*, 1999;11:55-62
- 75 Collins SM, Barbara G, Vallance B. Stress, inflammation and the irritable bowel syndrome. *Canad J Gastroentero*, 1999;13:47a-49a

Edited by Wu XN

Proofread by Zhu LH and Ma JY